The locations for a Marketing Authorisation Holder (MAH) and a Qualified Person responsible for Pharmacovigilance (QPPV) after the end of the transition period.
New rules for January 2021
The UK has left the EU, and the transition period after Brexit comes to an end this year.
This page tells you what you’ll need to do from 1 January 2021. It will be updated if anything changes.
Check what else you need to do during the transition period.
Qualified Person responsible for Pharmacovigilance (QPPV): UK requirements regarding legal presence
The MAH must have permanently and continuously at its disposal a QPPV who is responsible for the establishment and maintenance of the pharmacovigilance system for UK nationally authorised products.
The QPPV for UK nationally authorised products (including those that cover Northern Ireland, Great Britain or the whole of the UK) can reside and operate anywhere in the UK or the EU/EEA. Where the QPPV does not reside and operate in the UK, there will be a need for a national contact person for pharmacovigilance who resides and operates in the UK.
A UK located QPPV will not be accepted in EU Member states.
Establishment of the Marketing Authorisation Holder (MAH)
The marketing authorisation holder for a UK marketing authorisation (MAH) must be established in the UK (Great Britain or Northern Ireland) or in the EU/EEA. A UK marketing authorisation is one that is granted by the UK Licensing Authority to permit the sale or supply of a product in Great Britain, Northern Ireland or in both territories.
An exception to this requirement applies in the case of an application for a Great Britain marketing authorisation made through the unfettered access route in which the applicant seeks recognition in Great Britain of a Marketing Authorisation (MA) approved in Northern Ireland.
One of the conditions for eligibility for that route is that the MAH must be established in Northern Ireland.
A UK located MAH will not be accepted in EU Member States.